We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prognostic Panel Helps Identify Lupus Patients at Risk for Kidney, Brain, or Cardiovascular Involvement

By LabMedica International staff writers
Posted on 24 Jun 2014
In response to physician requests to help fulfill an unmet need, the new prognostic test helps assess potential risk of various Lupus related complications.

Lupus patients can suffer from disease flares that can become destructive to any organ or tissue in the body. Exagen Diagnostics, Inc. (Albuquerque, NM, USA), a leading diagnostics development company focused in rheumatology, has launched the addition of "Avise SLE Prognostic" to its testing services. Designed to supplement the "Avise SLE+ Connective Tissue" diagnostic, the Avise SLE Prognostic panel helps physicians assess potential risk for lupus nephritis, neuropsychiatric SLE (Systemic lupus erythematosus), thrombosis, and cardiovascular events.

The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space. The panel includes the following markers: anti-C1q – prognostic factor for lupus nephritis; anti-Ribosomal P – prognostic factor for neuropsychiatric SLE; and anti-phosphatidylserine/prothrombin (PS/PT) (IgM, IgG) – prognostic factor for thrombosis in SLE. Also, prognostic factors for thrombosis and cardiovascular events – anti-cardiolipin (IgM, IgG, IgA) and anti-β2-Glycoprotein 1 (IgM, IgG, IgA) – are indirectly included in the Avise SLE+ Connective Tissue 2.0 diagnostic or as an add-on to Avise SLE 2.0.

Complimenting Avise SLE 2.0 or Avise SLE+ Connective Tissue 2.0, Avise SLE Prognostic uses the same blood draw specimen as for the diagnostic and offers pre-provided kits, pre-paid Fedex, limited patient out-of-pocket cost, and high quality data based results within 7 days.

"We are pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients. This launch furthers our commitment to providing access to quality serologic testing to all patients," said Ron Rocca, Exagen President and CEO.

Related Links:
Exagen Diagnostics
Avise Tests



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Electrolyte Analyzer
CBS-4000 (CBS-400)

Latest Immunology News

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
24 Jun 2014  |   Immunology

Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
24 Jun 2014  |   Immunology

Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
24 Jun 2014  |   Immunology



INTEGRA BIOSCIENCES AG